May 26, 2022 / 09:00PM GMT
Operator
Thank you for standing by, and welcome to the Iovance Biotherapeutics Update Call. (Operator Instructions) As a reminder, today's call is being recorded.
I would now like to turn the conference to your host for today, Ms. Sara Pellegrino. Ma'am, you may begin.
Sara Pellegrino - Iovance Biotherapeutics, Inc. - VP of IR & Public Relations
Thank you, operator. Good evening, and thank you for joining us to discuss the positive clinical data for lifileucel to support our upcoming planned BLA submission in metastatic melanoma. During today's call, Dr. Fred Vogt, our Interim President and Chief Executive Officer, will provide a brief introduction; and Dr. Friedrich Finckenstein, our Chief Medical Officer, will further highlight the results from the C-144-01 melanoma study. Following these updates, we will hold a Q&A session. Additional Iovance team members taking part in the Q&A include Jean-Marc Bellemin, our Chief Financial Officer; Dr. Igor Bilinsky, our Chief Operating Officer; Dr. Madan Jagasia, SVP of Medical Affairs; Dr. Raj Puri, our
Iovance Biotherapeutics Inc to Discuss Updates for the C-144-01 Clinical Study Transcript
May 27, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers